Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Rhea-AI Summary

Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine for protein expression restoration, has announced its participation in two major investor conferences in March 2025:

• TD Cowen 45th Annual Healthcare Conference on Wednesday, March 5, 2025, at 9:50 a.m. ET
• Leerink Partners Global Healthcare Conference on Monday, March 10, 2025, at 10:40 a.m. ET

Live webcasts and archived replays of both presentations will be accessible through the Investors & News section of Stoke's website.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the following upcoming investor conferences:

TD Cowen 45th Annual Healthcare Conference
Date: Wednesday, March 5, 2025
Time: 9:50 a.m. ET

Leerink Partners Global Healthcare Conference
Date: Monday, March 10, 2025
Time: 10:40 a.m. ET

Live webcasts of each event, along with archived replays, will be available in the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for the Company’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250226132780/en/

Stoke Media & Investor Contacts:

Dawn Kalmar

Chief Communications Officer

dkalmar@stoketherapeutics.com

781-303-8302

Doug Snow

Director, Communications & Investor Relations

IR@stoketherapeutics.com

508-642-6485

Source: Stoke Therapeutics, Inc.

FAQ

When is Stoke Therapeutics (STOK) presenting at the TD Cowen Healthcare Conference in 2025?

Stoke Therapeutics will present at the TD Cowen Healthcare Conference on Wednesday, March 5, 2025, at 9:50 a.m. ET.

What time is STOK's presentation at the Leerink Partners Conference in March 2025?

STOK will present at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025, at 10:40 a.m. ET.

How can investors access Stoke Therapeutics (STOK) conference presentations?

Investors can access live webcasts and archived replays through the Investors & News section of Stoke's website at investor.stoketherapeutics.com.

What is the focus area of Stoke Therapeutics (STOK)?

Stoke Therapeutics is a biotechnology company that focuses on restoring protein expression by developing RNA medicines.